Schiff Hardin LLP advised CNS Pharmaceuticals, Inc. on the deal.CNS Pharmaceuticals, Inc. announced its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
